Tukysa shows durable responses in HER2+ mCRC

Rybrevant leads to anti-tumor activity and durable responses in CRC, phase I/II follow-up results show

Longer follow-up results from the investigational phase Ib/II OrigAMI-1 study evaluating amivantamab-vmjw, a bispecific antibody targeting epidermal growth factor receptor and MET, in combination with FOLFOX or FOLFIRI chemotherapy in patients with RAS/BRAF wild-type metastatic colorectal cancer were presented during a poster session at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.

January 16, 2026

Vol.52 No.02

Clinical Roundup

Fred Hutch researchers launch free online tool to assess CRC risk

Fred Hutch Cancer Center researchers developed a new tool that enables anyone to immediately assess their colorectal cancer risk online. Called MyGeneRisk, the free, web-based calculator allows users to input basic health information, including lifestyle habits and genetic data, to estimate their risk.

January 09, 2026

Vol.52 No.1

Guest Editorial

Mail-out colorectal cancer screening programs extend, rather than replace, clinical care

As a gastroenterologist, I’ve had the sobering experience of delivering a colorectal cancer diagnosis for far too many patients and family members. Some meant to get screened but never found the time. Others thought it didn’t apply to them or assumed it would be too inconvenient.

Xilio Therapeutics announces Phase II data for Vilastobart in MSS mCRC

Xilio Therapeutics announced data from its ongoing Phase II clinical trial evaluating vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab (Tecentriq) in patients with microsatellite stable metastatic colorectal cancer.

November 14, 2025

Vol.51 No.42

Clinical Roundup

Zanzalintinib + atezolizumab improve survival in advanced CRC

Combining zanzalintinib, a targeted therapy drug, and atezolizumab, an immune checkpoint inhibitor, helped patients with metastatic colorectal cancer live longer and control their disease better than with the standard treatment drug regorafenib, according to a study led by UCLA investigators.

October 24, 2025

Vol.51 No.39

Clinical Roundup

Researchers identify two groups of antigen-presenting fibroblasts that support survival and growth of malignant tumors

UT Southwestern Medical Center researchers have identified two distinct populations of cells known as antigen-presenting cancer-associated fibroblasts that appear to support the survival and growth of malignant tumors.

October 10, 2025

Vol.51 No.37

Tukysa shows durable responses in HER2+ mCRC

YOU MAY BE INTERESTED IN

Rybrevant leads to anti-tumor activity and durable responses in CRC, phase I/II follow-up results show

Fred Hutch researchers launch free online tool to assess CRC risk

Mail-out colorectal cancer screening programs extend, rather than replace, clinical care

Xilio Therapeutics announces Phase II data for Vilastobart in MSS mCRC

Zanzalintinib + atezolizumab improve survival in advanced CRC

Researchers identify two groups of antigen-presenting fibroblasts that support survival and growth of malignant tumors

Renew today!

Subscriber content

Never miss an issue!

Login